ArticleBMC gastroenterology2026
Fibrotic, metabolic and clinical improvements in patients with chronic hepatitis C treated with direct-acting antiviral therapy in a resource limited setting: a prospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) infection can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The advent of direct-acting antivirals (DAA) has transformed HCV treatment, achieving high cure rates. This study aimed to evaluate fibrotic, metabolic and clinical improvements in chronic HCV patients treated with DAA in low resource settings.
methodsAn institution-based prospective cohort study was conducted from February 1 to July 30, 2023 to collect data face-to-face using a structured questionnaire and data abstraction sheet. Statistical analysis was performed using Statistical Package for the Social Sciences version 26. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as frequencies and percentages. Paired t-tests were used to compare baseline, third and sixth months post sustained virologic response (SVR) data, with statistical significance set at P < 0.05.
resultsA total of 102 patients were enrolled (mean age 47.67 ± 12.7 years); and most were female (65.7%). Significant reductions were observed in liver enzymes: Aspartate aminotransferase and Alanine aminotransferase decreased at three and six month post-SVR (P < 0.001). Hepatic synthetic function improved, with serum albumin rising and international normalized ratio declining at both follow-ups (P < 0.001). Total bilirubin decreased significantly at three (P = 0.007) and six months (P = 0.001). Model for End Stage Liver Disease scores declined at three and six months (P < 0.001). Aspartate aminotransferase to Platelet ratio index scores and Fibrosis-4index score, demonstrated significant reductions at both follow up (P < 0.001).
conclusionsDirect-acting antivirals therapy in chronic HCV patients resulted in a statistically significant improvements in liver function, clinical outcomes, and fibrosis levels by the third and sixth months post SVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.